What the Keytruda Patent Expiry Means for Indian Patients
Pembrolizumab's Indian patent protection has been reported as beginning to lapse around 2028 to 2029. Until then, nothing about Keytruda's Indian price changes because of a patent. When protection does lapse, approved Indian biosimilars could narrow the price gap sharply, as nivolumab's did. That is two to three years away, and it is not a reason to postpone treatment that is needed now.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
What changes when the Keytruda patent expires in India, and when?
Pembrolizumab's Indian patent protection has been reported as beginning to lapse around 2028 to 2029. That is the earliest point at which an Indian pembrolizumab biosimilar could legally be sold. It is a reported window, not a fixed public date, and patent families usually lapse in stages. As of August 2026 no pembrolizumab biosimilar is approved and marketed in India.
The reason this question is being asked at all is nivolumab, the other PD-1 inhibitor in wide Indian use. Its Indian patent lapsed on 2 May 2026, and a domestic biosimilar reached patients even earlier, in January 2026, after a division bench of the Delhi High Court set aside an injunction that had blocked the launch. The Supreme Court of India declined to interfere on 11 February 2026. That sequence is what a patent story looks like when it lands well for patients — and it happened to a different molecule.
| Reported milestone | Date | What it means for a patient in India |
|---|---|---|
| First Indian nivolumab biosimilar launched (Tishtha, Zydus Lifesciences) | January 2026 | Reached patients ahead of the originator's patent expiry, under a Delhi High Court division bench order |
| Supreme Court declined to interfere with that order | 11 February 2026 | The biosimilar stayed on the market while the commercial dispute continued between the companies |
| Nivolumab's Indian patent lapsed | 2 May 2026 | Further nivolumab biosimilars from other manufacturers became possible over time |
| Pembrolizumab's Indian patent protection reported to begin lapsing | Around 2028–29 | The earliest point at which an Indian pembrolizumab biosimilar could be sold here |
| An approved Indian pembrolizumab biosimilar actually launches | Not announced | Expiry, approval and launch are three separate events; none of them is scheduled yet for this molecule |
Dates above are drawn from published reporting and company filings, as of August 2026. They are reported milestones, not commitments by any company or regulator, and they can move.
How much might Keytruda's price fall in India after the patent expires?
No one can put a reliable figure on it in advance. The only Indian evidence in this drug class is nivolumab, where the biosimilar was listed at approximately a quarter of the reference product's price. Whether pembrolizumab follows the same pattern depends on how many manufacturers reach approval, and when. None has yet.
| Molecule | Reference brand, published indicative price | Indian biosimilar, published price | Reported gap |
|---|---|---|---|
| Nivolumab | About ₹36,000 to over ₹90,000 per vial by dosage form (Business Standard reporting, 2026) | ₹13,950 for 40 mg and ₹28,950 for 100 mg (Zydus Lifesciences regulatory filing, 22 January 2026) | Described in that filing as approximately a quarter of the reference price |
| Pembrolizumab | MRP around ₹2.08 lakh per 100 mg vial, selling prices commonly reported at ₹1.5 lakh to ₹1.9 lakh (Indian pharmacy listings, August 2026) | None approved and marketed in India as of August 2026 | Not yet applicable |
Indicative only, as of August 2026, from published third-party listings, reporting and filings. These are not CION prices — CION Cancer Clinics quotes no rate against this or any named molecule.
Indian Express reported in April 2026 that at least seven Indian manufacturers were working on pembrolizumab versions, with expectations of a cheaper product in about two years. That is development activity, not an approval, and biosimilar timelines slip routinely. A first biosimilar also rarely delivers the full drop on its own; in most drug classes the larger fall comes later, once several approved products compete.
Two other things move the number in the opposite direction. The reference brand can respond with its own discounting or access terms, and manufacturers commonly introduce a reformulated version with fresh protection before an older one lapses. Neither is predictable from here. This page draws no comparison of quality between manufacturers — that judgement belongs to the regulator and to your treating team.
Should treatment be delayed to wait for a cheaper Keytruda?
No. A reported patent window two to three years away is not a treatment plan. A cancer does not pause while a price moves. Delay can shift a cancer to a stage where the options open today are no longer open, and no later price makes that back.
There is a second reason the wait does not work even in pure financial terms. Eligibility for immunotherapy is decided by cancer type, stage, biomarker results such as PD-L1, previous treatment and general fitness — assessed at the time you are seen. A patient who is a candidate in 2026 may not be one in 2029, and a cheaper vial is worth nothing to someone the medicine is no longer appropriate for.
Where cost is the real barrier, and for a great many Indian families it is, the useful questions are all about now rather than 2029. Four of them are worth putting to the treating oncologist and the hospital's scheme desk in writing:
- What is approved for this cancer today? Nivolumab's Indian price has already moved, and toripalimab entered the Indian market after May 2026. Whether either is an option depends entirely on the diagnosis and biomarker results, never on price — but it is a fair question to ask, and the answer may be yes.
- Does a manufacturer access programme apply? These run through hospital pharmacies and their terms are revised periodically, so the current structure should be confirmed in writing rather than assumed from an older account online.
- What will the scheme actually cover? Ayushman Bharat PM-JAY, Telangana's Aarogyasri and employee schemes carry package ceilings built around chemotherapy costs. Obtaining the applicable ceiling in writing before the first cycle is more useful than an estimate given verbally.
- What is the plan to the first response scan? Budgeting to the first response assessment, usually after three or four cycles, is more workable than planning against a two-year maximum from day one. That scan is the honest decision point for the money as well as for the medicine.
If treatment is genuinely unaffordable, the answer is a conversation with the treating team about the alternatives approved for that cancer — not a two-year wait for a price that may or may not arrive.
Who pembrolizumab is not for
Most patients seen in an Indian oncology clinic are not candidates for pembrolizumab, and a patent expiry does not change that by a single patient. It is approved only for specific cancer types, stages and biomarker results. If your diagnosis is not on that list, the price story on this page is not a decision you have to make at all.
Beyond the indication itself, pembrolizumab is generally unsuitable, or needs specialist reassessment before it is even considered, for people with an active autoimmune disease requiring ongoing systemic immunosuppression; solid-organ transplant recipients, in whom checkpoint blockade can trigger graft rejection; anyone who has already had a severe immune-related reaction to a checkpoint inhibitor; people taking high-dose steroids for another condition; and people who are pregnant or planning a pregnancy. Poor performance status shifts the balance too, because the risk of a serious immune reaction does not fall just because a patient is frailer.
This page is also not a quote, not a statement that any medicine is stocked or supplied at any particular place, and not a suitability check. Only the oncologist holding your reports can say whether pembrolizumab is an option for your cancer — and that question comes before the price, not after it.
How does an Indian biosimilar actually reach a patient?
A patent lapse is the first step of five, not the finish line. Each step takes its own time, and a molecule can stall at any of them. This is why "the patent expires in 2028" and "the price falls in 2028" are different statements.
- Protection ends, or a court permits a launch Expiry is the usual route. Nivolumab took the other one, reaching Indian patients in January 2026 under a court order months before the patent itself lapsed.
- The manufacturer completes similarity studies Under the Central Drugs Standard Control Organisation's similar biologics pathway, analytical, non-clinical and clinical work must show no clinically meaningful difference from the reference product.
- CDSCO grants approval, indication by indication A biosimilar's approved uses can be narrower than the reference brand's Indian label, and conditions such as a post-marketing study are often attached.
- The product is launched and priced Approval and launch are separate events. Supply volumes, cold-chain logistics and distribution decide how quickly a listed price becomes a price patients can obtain.
- Hospitals add it, and competition builds A hospital pharmacy has to stock it and a treating team has to be willing to use it. The steepest falls in most drug classes come once several approved products compete, not on day one.
What a patent expiry does not change
A price is only one line on an immunotherapy bill, and eligibility is not a line on it at all. Five things stay exactly as they are on the day protection lapses.
- Who is eligible Cancer type, stage, biomarker results and fitness decide this. A cheaper molecule that is not approved for your cancer is not an option at any price.
- What the medicine is approved to treat in India The Indian label, not the wider international one, governs what an oncologist here can prescribe — for the reference brand and for any biosimilar.
- The rest of the bill Day-care admission, nursing, pre-dose bloods, response scans coordinated at partner imaging centres, and the cost of managing an immune-related reaction are all billed separately and are unaffected by a patent.
- Scheme package ceilings Government scheme packages are revised on their own cycle. A lower drug price does not automatically raise, or make redundant, a ceiling that was built around chemotherapy costs.
- The safety profile and the monitoring it needs An immune checkpoint inhibitor at a quarter of the price still needs the same pre-dose monitoring and the same rapid response to a suspected immune-related side effect.
Why does a coming price drop raise the risk of counterfeit vials?
Because the gap between what the medicine costs and what families can pay is exactly the gap an informal market fills. An International Consortium of Investigative Journalists investigation published in April 2026 documented counterfeit Keytruda reaching patients and even hospitals in several countries, and Indian reporting the same month placed India inside that market.
The pattern reported around patent and exclusivity changes is consistent: talk of a cheaper version arriving makes an unusually cheap offer sound plausible, and the families targeted are precisely the ones who cannot afford the genuine product. A vial offered far below the published range is a warning sign, not a bargain, and a fake cannot be identified by appearance alone.
Three protections cost nothing. Obtain medicines only through a licensed hospital or hospital-empanelled pharmacy, against an invoice carrying the batch number and expiry printed on the carton. Check the carton before it is opened for a tampered seal, a batch number that does not match the invoice, or a solution that looks unlike previous cycles. Insist on a documented cold chain, because a checkpoint inhibitor stored outside 2–8 °C is unusable whether or not it is genuine.
Counterfeit Immunotherapy Drugs in India: How to Protect Yourself sets out how the fake supply chain works and what has been documented here. How to Verify an Immunotherapy Vial Is Genuine is the step-by-step check to run at the pharmacy counter. And if anyone has suggested sourcing a vial privately to save money, Buying Immunotherapy Medicines Outside the Hospital: Risks and Rules explains why that is the single riskiest way to act on a price story like this one.
This is patient-safety information. Nothing here implies where any medicine should be obtained, or by whom it is supplied.
Keytruda Patent Expiry in India: Frequently Asked Questions
When does the Keytruda patent expire in India?
Pembrolizumab's Indian patent protection has been reported as beginning to lapse around 2028 to 2029. That is a reported window rather than a single fixed date, and patent families usually lapse in stages instead of all at once. Nivolumab is the recent Indian comparison: its Indian patent lapsed on 2 May 2026, although a biosimilar had already launched in January 2026 under a Delhi High Court order. As of August 2026 no pembrolizumab biosimilar is approved and marketed in India.
How much could Keytruda's price fall in India after the patent lapses?
No reliable number can be put on it in advance. The only Indian evidence in this drug class so far is nivolumab. Zydus Lifesciences' regulatory filing of 22 January 2026 listed its nivolumab biosimilar at ₹13,950 for a 40 mg vial and ₹28,950 for a 100 mg vial, described in that filing as approximately a quarter of the reference product's price, against published reference prices of about ₹36,000 to over ₹90,000 per vial by dosage form. Whether pembrolizumab follows the same pattern depends on how many manufacturers reach approval and launch, which is not yet known.
Should treatment be delayed until a cheaper version of Keytruda arrives?
No. A reported patent window two to three years away is not a treatment plan, and a cancer does not pause while a price moves. Delay can shift a cancer to a stage at which the options open today are no longer open, and eligibility for immunotherapy is decided by diagnosis, stage, biomarker results and fitness at the time of assessment, not by the price of a vial. Where cost is the barrier, the useful conversation with the treating oncologist now is about the options approved for that specific cancer today, scheme cover, and manufacturer access programmes.
Is a biosimilar the same medicine as the original brand?
A biosimilar is not a generic copy. Under the Central Drugs Standard Control Organisation's similar biologics pathway, a manufacturer has to run its own analytical, non-clinical and clinical similarity studies and show there is no clinically meaningful difference from the reference product. Approval then applies only to the indications granted, which can be narrower than the reference brand's Indian label. This page makes no quality comparison between named manufacturers; that assessment sits with the regulator and with the treating team.
Why do counterfeit vials become a bigger risk around a patent expiry?
Because a wide gap between what a medicine costs and what families can pay creates a market for informal supply. An International Consortium of Investigative Journalists investigation published in April 2026 documented counterfeit Keytruda reaching patients and hospitals in several countries, and Indian reporting the same month placed India inside that market. A vial offered far below published prices is a warning sign rather than a bargain. Obtaining medicines only through a licensed hospital or hospital-empanelled pharmacy, with an invoice carrying the batch number and expiry, is the practical protection.
Does a patent expiry change who can have immunotherapy?
No. Eligibility is decided by cancer type, stage, biomarker results such as PD-L1, previous treatment and general fitness, and by what is approved in India for that situation. Price has no bearing on it. A cheaper medicine that is not approved for a particular cancer is not an option at any price, and most patients seen in an Indian oncology clinic are not candidates for checkpoint-inhibitor treatment at all.